Longboard Pharmaceuticals, Inc. Proceeds from Common Stock Issued
Longboard Pharmaceuticals, Inc. reported Proceeds from Common Stock Issued of $301.35 million for the 9-month period ending 2024-09-30, per its 10-Q filed 2024-11-07.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfCommonStock · last filed 2024-11-07
- Longboard Pharmaceuticals, Inc. proceeds from issuance of common stock for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- Longboard Pharmaceuticals, Inc. proceeds from issuance of common stock for the quarter ending 2024-06-30 was $0.00.
- Longboard Pharmaceuticals, Inc. proceeds from issuance of common stock for the quarter ending 2024-03-31 was $301.35M, a 1210.22% increase year-over-year.
- Longboard Pharmaceuticals, Inc. proceeds from issuance of common stock for the quarter ending 2023-12-31 was $2.83M.
- Longboard Pharmaceuticals, Inc. proceeds from issuance of common stock for fiscal 2023 was $31.79M.
- Longboard Pharmaceuticals, Inc. proceeds from issuance of common stock for fiscal 2022 was $0.00.
- Longboard Pharmaceuticals, Inc. proceeds from issuance of common stock for fiscal 2020 was $3.20M.
| Period end | Proceeds from Issuance of Common Stock 3 month | Proceeds from Issuance of Common Stock 6 month | Proceeds from Issuance of Common Stock 9 month | Proceeds from Issuance of Common Stock 12 month |
|---|---|---|---|---|
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $0.00 derived: sum of 2 quarters · filed 2024-11-07 | $301.35M 10-Q · filed 2024-11-07 | $304.18M derived: sum of 4 quarters · filed 2024-11-07 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $301.35M 10-Q · filed 2024-08-01 | $304.18M derived: sum of 3 quarters · filed 2024-08-01 | $310.14M derived: sum of 4 quarters · filed 2024-11-07 |
| 2024-03-31 | $301.35M 10-Q · filed 2024-05-02 | $304.18M derived: sum of 2 quarters · filed 2024-05-02 | $310.14M derived: sum of 3 quarters · filed 2024-11-07 | $310.14M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-12-31 | $2.83M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | $8.79M derived: sum of 2 quarters · filed 2024-11-07 | $8.79M derived: sum of 3 quarters · filed 2024-11-07 | $31.79M 10-K · filed 2024-03-12 |
| 2023-09-30 | $5.96M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $5.96M derived: sum of 2 quarters · filed 2024-11-07 | $28.96M 10-Q · filed 2024-11-07 | $28.96M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $23.00M 10-Q · filed 2024-08-01 | $23.00M derived: sum of 3 quarters · filed 2024-08-01 | |
| 2023-03-31 | $23.00M 10-Q · filed 2024-05-02 | $23.00M derived: sum of 2 quarters · filed 2024-05-02 | ||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | $0.00 10-K · filed 2024-03-12 | ||
| 2022-09-30 | $0.00 10-Q · filed 2023-11-02 | |||
| 2020-12-31 | $3.20M 10-K · filed 2022-03-03 | |||
| 2020-09-30 | $924.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $2.16M derived: sum of 2 quarters · filed 2021-11-04 | $2.20M 10-Q · filed 2021-11-04 | |
| 2020-06-30 | $1.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $1.28M 10-Q · filed 2021-08-09 | ||
| 2020-03-31 | $39.00K 10-Q · filed 2021-05-10 |